PubRank

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Clinical Trial ID NCT01358877

PubWeight™ 40.07‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01358877

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011 4.12
2 Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. J Clin Oncol 2015 2.17
3 Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol 2015 1.99
4 Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast 2013 1.94
5 Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol 2015 1.88
6 Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res 2014 1.43
7 Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med 2017 1.43
8 Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist 2013 1.35
9 Targeted therapy for HER2 positive breast cancer. J Hematol Oncol 2013 1.19
10 Treatment of HER2-positive breast cancer. Breast 2013 1.09
11 Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med 2015 0.93
12 Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer. Int J Breast Cancer 2012 0.92
13 Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist 2014 0.89
14 Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Transl Med 2014 0.86
15 Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy. J Oncol 2013 0.84
16 Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer. Breast Cancer 2013 0.79
17 Treatment of early-stage HER2+ breast cancer-an evolving field. Ecancermedicalscience 2015 0.79
18 Role of pertuzumab in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) 2012 0.79
19 First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces? J Exp Clin Cancer Res 2016 0.78
20 Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nat Rev Clin Oncol 2016 0.78
21 Breast cancer: Increasing therapy options for HER2-positive early breast cancer. Nat Rev Clin Oncol 2011 0.78
22 Precision medicine and personalized breast cancer: combination pertuzumab therapy. Pharmgenomics Pers Med 2014 0.77
23 Alternative targeted therapy for early Her2 positive breast cancer. Gland Surg 2013 0.77
24 Trial watch: ERBB2 dimerization inhibitor meets end point in breast cancer trial. Nat Rev Drug Discov 2011 0.77
25 Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations. Int J Womens Health 2014 0.75
26 Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) 2015 0.75
27 Changing Paradigms in Breast Cancer Therapeutics: An Extended Abstract. Med Princ Pract 2015 0.75
28 Adjuvant trastuzumab: does time really matter? Oncologist 2013 0.75
29 Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan. Mol Clin Oncol 2015 0.75
30 Patterns in target-directed breast cancer research. Springerplus 2016 0.75
31 Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis. PLoS Med 2016 0.75
32 Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. Hosp Pract (1995) 2012 0.75
33 Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab. Cancer Manag Res 2016 0.75
34 Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term. Breast Cancer Res 2012 0.75
35 Monoclonal antibodies and Fc fragments for treating solid tumors. Biologics 2012 0.75
36 Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer. Target Oncol 2016 0.75
37 Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. Pharmacogenomics J 2016 0.75
38 The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity. MAbs 2016 0.75
39 Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open 2016 0.75
40 Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients. Breast Cancer (Dove Med Press) 2014 0.75
Next 100